Neuroscience research is evolving rapidly, bringing new opportunities and challenges in disease modeling, colony management, breeding strategy, and translational discovery. In this video series, Taconic's scientific experts share practical insights drawn from their hands-on experience supporting researchers in biotech, pharmaceutical, and academic organizations.
Episode 1
Alzheimer's disease is highly heterogeneous, making it difficult for any single preclinical model to capture the full complexity of human disease biology and therapeutic response. In this episode, Dr. Janell Richardson explores emerging approaches to Alzheimer's disease modeling and discusses how advanced preclinical platforms can help researchers investigate genotype-dependent differences and improve translational relevance.
Episode 2—Coming Soon
Producing study-ready cohorts of neurological disease models often requires careful planning around breeding performance, phenotype development, aging, and attrition. In this episode, Dr. Caroline Mallick-Wood shares insights for anticipating these challenges and designing breeding programs that support neuroscience research.
Director, Portfolio Management Neurobiology and Rare Disease
Dr. Sarah Sterlace helps make innovative in vivo models and services accessible to neuroscience researchers around the world. With extensive experience translating complex research challenges into practical solutions, she partners with scientists across biotech, pharmaceutical, and academic organizations to advance preclinical discovery. Through these conversations, Sarah helps viewers explore emerging research approaches, model selection strategies, and opportunities to accelerate scientific progress.
Director, R&D
Dr. Janell Richardson leads the development of innovative research models and technologies that help advance translational science. Her work focuses on creating solutions that enable researchers to investigate complex disease biology with greater precision and confidence. In this series, Janell explores emerging approaches to Alzheimer's disease modeling and discusses how advanced preclinical platforms can help scientists better understand genotype-dependent disease mechanisms and therapeutic responses.
